Bioventus Inc - Ordinary Shares - Class A Stock

$6.54

0.15% yesterday

Nasdaq, Jul 29, 10:00 pm CET

ISIN

US09075A1088

Symbol

BVS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

Bioventus Inc - Ordinary Shares - Class A Stock price

$6.54

-6.46 49.69% 5Y

Nasdaq, Closing price Tue, Jul 29 2025

+0.01 0.15%

ISIN

US09075A1088

Symbol

BVS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

$536.4m

Enterprise Value

$869.8m

Net debt

$333.4m

Cash

$22.8m

Shares outstanding

82.0m

Valuation (TTM | estimate)

P/E

negative | 9.2

P/S

0.9 | 0.9

EV/Sales

1.5 | 1.5

EV/FCF

36.3

P/B

3.6

Financial Health

Equity Ratio

20.3%

Return on Equity

-22.7%

ROCE

4.7%

ROIC

3.3%

Debt/Equity

2.4

Financials (TTM | estimate)

Revenue

$567.7m | $571.0m

EBITDA

$31.7m | $114.9m

EBIT

$24.2m | $104.8m

Net Income

$-31.6m | $58.5m

Free Cash Flow

$23.9m

Growth (TTM | estimate)

Revenue

8.6% | -0.4%

EBITDA

12.2% | 256.1%

EBIT

22.3% | 325.6%

Net Income

-45.9% | 274.5%

Free Cash Flow

767.0%

EPS

$-0.5

FCF per Share

$0.3

Short interest

6.3%

Employees

Rev per Employee

$560.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Bioventus Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Bioventus Inc - Ordinary Shares - Class A forecast:

5x Buy

71%

2x Hold

29%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Bioventus Inc - Ordinary Shares - Class A forecast:

Buy

71%

Hold

29%

Analyst Estimates with Stock Price Targets

Financial data from Bioventus Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	568 568	9% 9% 100%
- Direct Costs	185 185	3% 3% 33%
Gross Profit	383 383	12% 12% 67%
- Selling and Administrative Expenses	336 336	11% 11% 59%
- Research and Development Expense	14 14	15% 15% 2%
EBITDA	32 32	12% 12% 6%
- Depreciation and Amortization	7.49 7.49	11% 11% 1%
EBIT (Operating Income) EBIT	24 24	22% 22% 4%
Net Profit	-32 -32	46% 46% -6%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Bioventus Inc - Ordinary Shares - Class A Stock News

Neutral

GlobeNewsWire

●

about 7 hours ago

Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025

DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market opens on Wednesday, August 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that sa...

Neutral

Seeking Alpha

●

3 months ago

Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript

Bioventus Inc. (NASDAQ:BVS ) Q1 2025 Results Conference Call May 6, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Robbie Marcus - JPMorgan Operator Good day, and welcome to the Bioventus Fir...

Neutral

GlobeNewsWire

●

3 months ago

Bioventus Reports First Quarter Financial Results

DURHAM, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 29, 2025.

More Bioventus Inc - Ordinary Shares - Class A News

Company Profile

Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from a array of musculoskeletal conditions. It operates through four segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on December 22, 2015 and is headquartered in Durham, NC.

Head office	United States
CEO	Robert Claypoole
Employees	1,030
Founded	2011
Website	www.bioventus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now